Dabrafenib plus trametinib (D + T) as adjuvant treatment of resected <i>BRAF</i>-mutant stage III melanoma: Findings from the COMBI-AD trial analyzed based on AJCC 8 classification.James Larkin, Georgina V. Long, Marta Nyakas et al.|Journal of Clinical Oncology|2018Cited by 11
Effect on health-related quality of life (HRQOL) of adjuvant treatment (tx) with dabrafenib plus trametinib (D + T) in patients (pts) with resected stage III <i>BRAF</i>-mutant melanoma.Dirk Schadendorf, Georgina V. Long, Axel Hauschild et al.|Journal of Clinical Oncology|2018Cited by 10
Mutational and immune gene expression profiling at relapse in patients (pts) treated with adjuvant dabrafenib plus trametinib (D + T) or placebo (pbo) in the COMBI-AD trial.Reinhard Dummer, Georgina V. Long, Axel Hauschild et al.|Journal of Clinical Oncology|2018Cited by 1